Skip to content
Preprint · CC-BY via OpenAlex

Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders

Matthew D. Wiefels, Emily Furar, Rebecca S. Eshraghi, Jeenu Mittal, Idil Memis, Moeed Moosa, Rahul Mittal, Adrien A. Eshraghi

Current Neuropharmacology · 2022 · ▲ 25 citations

Abstract

The gut microbiota, composed of numerous species of microbes, works in synergy with the various organ systems in the body to bolster our overall health and well-being. The most well-known function of the gut microbiome is to facilitate the metabolism and absorption of crucial nutrients, such as complex carbohydrates, while also generating vitamins. In addition, the gut microbiome plays a crucial role in regulating the functioning of the central nervous system (CNS). Host genetics, including specific genes and single nucleotide polymorphisms (SNPs), have been implicated in the pathophysiology of neurological disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), and autism spectrum disorder (ASD). The gut microbiome dysbiosis also plays a role in the pathogenesis of these neurodegenerative disorders, thus perturbing the gut-brain axis. Overproduction of certain metabolites synthesized by the gut microbiome, such as short-chain fatty acids (SCFAs) and p-cresyl sulfate, are known to interfere with microglial function and trigger misfolding of alpha-synuclein protein, which can build up inside neurons and cause damage. By determining the association of the gut microbiome and its metabolites with various diseases, such as neurological disorders, future research will pave the way for the development of effective preventive and treatment modalities.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.2174/1570159x20666221003085508
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Wiefels, M.D., Furar, E., Eshraghi, R.S., Mittal, J., Memis, I., Moosa, M., Mittal, R., &amp; Eshraghi, A.A. (2022). Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders. <em>Current Neuropharmacology</em>. https://doi.org/10.2174/1570159x20666221003085508
Vancouver
Wiefels MD, Furar E, Eshraghi RS, Mittal J, Memis I, Moosa M, et al. Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders. Current Neuropharmacology. 2022. doi:10.2174/1570159x20666221003085508.
BibTeX
@unpublished{matthew2022Target, title = {Targeting Gut Dysbiosis and Microbiome Metabolites for the Development of Therapeutic Modalities for Neurological Disorders}, author = {Matthew D. Wiefels and Emily Furar and Rebecca S. Eshraghi and Jeenu Mittal and Idil Memis and Moeed Moosa and Rahul Mittal and Adrien A. Eshraghi}, journal = {Current Neuropharmacology}, year = {2022}, doi = {10.2174/1570159x20666221003085508}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings